News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Veloxis Pharmaceuticals A/S (VELO) Release: Phase 3 Clinical Study Data Demonstrating LCP-Tacro™’s Comparable Efficacy and Safety to Twice-Daily Tacrolimus Presented at the European Society for Organ Transplantation



9/4/2013 9:44:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the 3002, randomized, double-blind, double-dummy, Phase III study in 543 de novo kidney transplant patients will be presented at the European Society for Organ Transplantation as a late-breaker oral presentation at 8:30 a.m. CEST, Sept. 9, in Vienna. Veloxis’ once-daily LCP-Tacro™, now with the trade name of Envarsus®, demonstrated comparable efficacy and safety compared to twice-daily tacrolimus (Prograf®).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES